Search company, investor...

Onconova Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Onconova Therapeutics

Onconova Therapeutics, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The companys clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development.

Headquarters Location

375 Pheasant Run

Newtown, Pennsylvania, 18940,

United States


Missing: Onconova Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Onconova Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Onconova Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Onconova Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Onconova Therapeutics Patents

Onconova Therapeutics has filed 13 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Fluoroarenes
  • Monoclonal antibodies
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Organic sodium salts, Prodrugs, Fluoroarenes, Sodium compounds


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Organic sodium salts, Prodrugs, Fluoroarenes, Sodium compounds



Latest Onconova Therapeutics News

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

May 25, 2023

Newtown, Pennsylvania, UNITED STATES NEWTOWN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy. “There is an urgent need for new treatment approaches in metastatic melanoma, as 40 to 60% of these patients currently see little to no clinical benefit from PD-1 inhibitors,” said Ann Richmond, Ph.D., Ingram Professor of Pharmacology and Medicine at the Vanderbilt University School of Medicine and Senior Research Career Scientist at TVHS, Department of Veterans Affairs (Nashville). “The limited efficacy of these agents is often due to ‘cold’ tumor microenvironments (TME) that prevent the infiltration of immune effector cells. Peer-reviewed preclinical studies1 suggest rigosertib can enhance the efficacy of immune checkpoint blockade in metastatic melanoma by reversing cold TMEs, providing a strong scientific rationale for this clinical trial.” Douglas B. Johnson, M.D., M.S.C.I., Associate Professor of Medicine of Hematology/Oncology at Vanderbilt University Medical Center and Principal Investigator of the trial commented, “Rigosertib combined with anti-PD-1 therapy has shown clinical activity in checkpoint inhibitor refractory lung cancer patients, and we believe this promising finding may translate to melanoma. The newly initiated Phase 2 study has been thoughtfully designed to begin exploring this hypothesis and will afford participants the opportunity to receive a novel therapeutic combination that may lead to improved clinical outcomes. I look forward to conducting the study and to the important scientific insights I expect it will provide.” The investigator-sponsored Phase 2 trial is an open-label, two-stage, single arm study. Stage 1 of the trial is expected to include ten patients. If a pre-specified response criteria is met, the study will then proceed to Stage 2, during which an additional 19 patients are expected to be enrolled. Patients in the study will receive 560 mg of oral rigosertib twice daily on days 1-21 of 28-day treatment cycles, plus 400 mg of pembrolizumab administered via intravenous infusion every six weeks. The primary endpoint of the trial is overall response rate, while key secondary endpoints include assessments of safety, tolerability, progression-free survival, and overall survival. Correlative biomarker assessments will also be conducted. Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, “Rigosertib’s investigator-sponsored trials are an important component of our corporate strategy that allows us to diversify the indications studied with our pipeline while remaining internally focused on our lead narazaciclib program. We are thrilled to be collaborating with Vanderbilt’s world-class physician-scientists on this latest trial and look forward to its advancement.” For additional information on the Phase 2 trial, see identifier NCT05764395 . References: Yan, C., Saleh, N., Yang, J. et al. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Mol Cancer 20, 85 (2021). . About Onconova Therapeutics, Inc. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in a combination trial with estrogen blockade in advanced endometrial cancer. Based on preclinical and clinical studies of CDK 4/6 inhibitors, Onconova is also evaluating opportunities for combination studies with narazaciclib in additional indications. Onconova’s product candidate rigosertib is being studied in multiple investigator-sponsored studies. These studies include a dose-escalation and expansion Phase 1/2a study of oral rigosertib in combination with nivolumab in patients with KRAS+ non-small cell lung cancer, a Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC), and a Phase 2 trial evaluating rigosertib in combination with pembrolizumab in patients with metastatic melanoma. For more information, please visit . Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding its clinical development and trials, its product candidates, its business and financial position. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” “encouraging,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:

Onconova Therapeutics Frequently Asked Questions (FAQ)

  • When was Onconova Therapeutics founded?

    Onconova Therapeutics was founded in 1998.

  • Where is Onconova Therapeutics's headquarters?

    Onconova Therapeutics's headquarters is located at 375 Pheasant Run, Newtown.

  • What is Onconova Therapeutics's latest funding round?

    Onconova Therapeutics's latest funding round is IPO.

  • How much did Onconova Therapeutics raise?

    Onconova Therapeutics raised a total of $165.63M.

  • Who are the investors of Onconova Therapeutics?

    Investors of Onconova Therapeutics include Baxter, ICICI Venture, Riverstone Holdings, Mehta Partners, Leukemia & Lymphoma Society and 4 more.

  • Who are Onconova Therapeutics's competitors?

    Competitors of Onconova Therapeutics include AVEO Oncology, Radius, Kiadis Pharma, Aquinox Pharmaceuticals, Neuraltus Pharmaceuticals and 13 more.

Compare Onconova Therapeutics to Competitors

Radius Logo

Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.


Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.

Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

Cardeon Corporation

Cardeon Corporation is engaged in developing solutions for stroke prevention


Renovo provides drug discovery and development for scar prevention and reduction.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.